Announced
Completed
Synopsis
Longitude Capital, a healthcare venture capital firm, and Enavate Sciences, a platform dedicated to supporting therapeutic companies advancing medicines and enabling technologies, led a $60m Series A funding round in OrsoBio, a clinical-stage biopharmaceutical company, with participation from Samsara BioCapital, NuevaBio, and Eli Lilly and Company. “We are thrilled to welcome our new investors and for the continued support from our existing investors,” Mani Subramanian, OrsoBio CEO and Founder.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.